Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?

References

• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). J Clin Oncol. 2019;37(4):186.
   Web of Science ®Google Scholar
• Ueshima K, Nishida N, Hagiwara S, et al. Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study. Cancers (Basel). 2019;11:952.
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Kakizaki S, Nagashima T, et al. Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter retrospective study. Hepatol Res. 2020;50:382–395.
   PubMed Web of Science ®Google Scholar
• Sasaki R, Fukushima M, Haraguchi M, et al. Response to lenvatinib is associated with optimal relativedose intensity in hepatocellular carcinoma: experience in clinical settings. Cancers (Basel). 2019;11:1769.
   PubMed Web of Science ®Google Scholar
• Sho T, Suda G, Ogawa K, et al. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. Hepatol Res. 2020;50:966–977.
   PubMed Web of Science ®Google Scholar
• Ogushi K, Chuma M, Uojima H, et al. Safety and efficacy of lenvatinib treatment in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice: a multicenter analysis. Clin Exp Gastroenterol. 2020;13:385–396.
   PubMed Web of Science ®Google Scholar
• Maruta S, Ogasawara S, Ooka Y, et al. Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma. Liver Cancer. 2020;9:382–396.
   PubMed Web of Science ®Google Scholar
• Ohki T, Sato K, Kondo M, et al. Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Drugs Real World Outcomes. 2020;7:141–149.
   PubMedGoogle Scholar
• Hiraoka A, Kumada T, Atsukawa M, et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions—Multicenter analysis. Cancer Med. 2019;8(8):3719–3728.
   PubMed Web of Science ®Google Scholar
• Briggs A, Daniele B, Dick K, et al. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. Br J Cancer. 2020;122(12):1754–1759.
   PubMed Web of Science ®Google Scholar
• Sho T, Morikawa K, Kubo A, et al. Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. World J Gastrointest Oncol. 2021;13(12):2076–2087.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• A-A GK, George L, Masatoshi K, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM. 2022.
   Google Scholar
• Kelley RK, Rimassa L, Cheng A-L, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2022:1–14.
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of lenvatinib plus pembrolizumab in uHCC. J Clin Oncol. 2020;38(26):2960–2970.
   PubMed Web of Science ®Google Scholar
• Kudo M, Arizumi T, Ueshima K, et al. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi’s subclassification (Kinki criteria). Dig Dis. 2015;33:751–758.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child–pugh A liver function: a proof-of-concept study. Cancers (Basel). 2019;11(8):1084.
   PubMed Web of Science ®Google Scholar
• Shimose S, Kawaguchi T, Tanaka M, et al. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: a multicenter cohort study using data mining analysis. Oncol Lett. 2020;20(3):2257–2265.
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Scartozzi M, Tada T, et al. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis. Liver Int. 2021;00:1–9.
   Google Scholar
• Shimose S, Iwamoto H, Tanaka M, et al. Alternating lenvatinib and trans-arterial therapy prolongs overall survival in patients with intermediate stage hepatoCellular carcinoma: a propensity score matching study. Cancers (Basel). 2021;13:160.
   PubMed Web of Science ®Google Scholar
• Burgio V, Iavarone M, Di Costanzo GG, et al. Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy. Cancer Manag Res. 2021;13:9379–9389.
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: a phase 3, multicenter, randomized controlled trial. J Clin Oncol. 2022;40(4suppl):380.
   Google Scholar
• Tomonari T, Sato Y, Tanaka H, et al. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: three case reports. Medicine (Baltimore). 2020;99:42(e22782.
   PubMed Web of Science ®Google Scholar
• Myers S, Neyroud-Caspar I, Spahr L, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021;3(2):100231.
   PubMedGoogle Scholar
• Younossi Z, Stepanova M, Ong JP, et al. Global nonalcoholic steatohepatitis council. nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–755.e3.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Puzzoni M, Montagnani F, et al. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. Onco Targets Ther. 2019;12:2981–2988.
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–456.
   PubMed Web of Science ®Google Scholar
• Rimini M, Kudo M, Tada T, et al. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open. 2021;6(6):100330.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Tada T, et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep. 2021;11(1):16663.
   PubMed Web of Science ®Google Scholar
• Kim BK, Cheon J, Kim H, et al. Atezolizumab/Bevacizumab vs. Lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. Cancers (Basel). 2022;14(7):1747.
   PubMed Web of Science ®Google Scholar
• Rimini M, Rimassa L, Ueshima K, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7(6):100591.
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Rimini M, Kudo M, et al. REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study. Liver Cancer. 2022. DOI:10.1159/000525145.
   PubMed Web of Science ®Google Scholar
• Huynh J, Cho MT, J-H KE, et al. Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN). J Clin Oncol. 2021;39(3):298.
   Web of Science ®Google Scholar
• Terashima T, Yamashita T, Takata N, et al. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatol Res. 2020;50(7):871–884.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Atsukawa M, et al. Early relative change in hepatic function with lenvatinib for unresectable hepatocellular carcinoma. Oncology. 2019;97(6):334–340.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med. 2019;8:137–146.
   PubMed Web of Science ®Google Scholar
• Kodama K, Kawaoka T, Namba M, et al. Correlation between early tumor marker response and imaging response in patients with advanced hepatocellular carcinoma treated with lenvatinib. Oncology. 2019;97(2):75–81.
   PubMed Web of Science ®Google Scholar
• Saeki I, Yamasaki T, Yamashita S, et al. Early predictors of objective response in patients with hepatocellular carcinoma undergoing lenvatinib treatment. Cancers (Basel). 2020;12(4):779.
   PubMed Web of Science ®Google Scholar
• Liu B, Shang X, Shi J-Y, et al. Early Alpha-fetoprotein response is associated with survival in patients with hbv-related hepatocellular carcinoma receiving lenvatinib. Front Oncol. 2022;12:807189.
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Hiraoka A, et al. Neutrophil–lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with Lenvatinib. Liver Int. 2020;40(4):968–976.
   PubMed Web of Science ®Google Scholar
• Rimini M, Shimose S, Lonardi S, et al. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: a multi-institutional matched case-control study. Hepatol Res. 2021;51(12):1229–1241.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Michitaka K, Ueki H, et al. Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2016;28(8):940–947.
   PubMed Web of Science ®Google Scholar
• Uojima H, Chuma M, Tanaka Y, et al. Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib. Liver Cancer. 2020;9(2):193–206.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Kariyama K, et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol. 2021;36(7):1812–1819.
   PubMed Web of Science ®Google Scholar
• Shimose S, Kawaguchi T, Iwamoto H, et al. Controlling nutritional status (conut) score is associated with overall survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter cohort study. Nutrients. 2020;12(4):1076.
   PubMed Web of Science ®Google Scholar
• Rapposelli IG, Shimose S, Kumada T, et al. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. ESMO Open. 2021;6(4):100190.
   PubMed Web of Science ®Google Scholar
• Rimini M, Kang W, Burgio V, et al. Validation of the easy-to-use lenvatinib prognostic (LEP) index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Hepatol Res. 2022 Dec;52(12):1050-1059. DOI: 10.1111/hepr.13824. Epub 2022 Aug 25. PMID: 35960789.
   Web of Science ®Google Scholar
• Sung MW, Finn RS, Qin S, et al. Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT). J Clin Oncol. 2019;37(4):317.
   Web of Science ®Google Scholar
• Shimose S, Iwamoto H, Niizeki T, et al. Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Cancers (Basel). 2020;12(7):1867.
   PubMed Web of Science ®Google Scholar
• Rapposelli IG, Tada T, Shimose S, et al. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver Int. 2021;41:2997–3008.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52:512–519.
   PubMed Web of Science ®Google Scholar
• Koizumi Y, Hirooka M, Hiraoka A, et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocr J. 2019;66(9):787–792.
   PubMed Web of Science ®Google Scholar
• Shomura M, Okabe H, Sato E, et al. Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy. Cancers (Basel). 2020;12(11):3078.
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Hiraoka A, et al. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching. Hepatol Res. 2020;50(1):75–83.
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Suzuki H, Shimose S, et al. Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers (Basel). 2020;12(4):1010.
   PubMed Web of Science ®Google Scholar
• Takahashi A, Moriguchi M, Seko Y, et al. Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma. Anticancer Res. 2019;39(9):5149–5156.
   PubMed Web of Science ®Google Scholar
• Eso Y, Nakano S, Mishima M, et al. Dose intensity/body surface area ratio is a novel marker useful for predicting response to lenvatinib against hepatocellular carcinoma. Cancers (Basel). 2019;12(1):49.
   PubMed Web of Science ®Google Scholar
• Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis
   Google Scholar
• Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis
   Google Scholar
• Chuma M, Yokoo H, Hiraoka A, et al. Identification of CT values that could be predictive of necrosis (N-CTav) in hepatocellular carcinoma after lenvatinib treatment. Curr Oncol. 2022;29:3259–3271.
   PubMed Web of Science ®Google Scholar
• Ohki T, Sato K, Kondo M, et al. Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma. Anticancer Res. 2019;39(9):5149–5156.
   PubMed Web of Science ®Google Scholar
• Hata K, Suetsugu K, Egashira N, et al. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol. 2020;86(6):803–813.
   PubMed Web of Science ®Google Scholar
• Finn RS, Kudo M, Cheng AL, et al. Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. Ann Oncol. 2017;28(5):v605–v649.
   Google Scholar
• Chuma M, Uojima H, Numata K, et al. Early changes in circulating FGF19 and ANG-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma. Cancers (Basel). 2020;12(2):293.
   PubMed Web of Science ®Google Scholar
• Shigesawa T, Suda G, Kimura M, et al. Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH Open. 2020;4(5):880–888.
   PubMed Web of Science ®Google Scholar
• Eso Y, Nakano S, Mishima M, et al. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci . 2021;00:1–10.
   Google Scholar
• Myojin Y, Kodama T, Maesaka K, et al. ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma. Clin Cancer Res. 2021;27(4):1150–1161.
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu J, Du Q, et al. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating ß-catenin. Transl Oncol. 2021;14(6):101059.
   PubMed Web of Science ®Google Scholar